Physician profile
Erin M Dodd
NPI 1285166231
$8,995.38
in general payments reported to CMS, 2019-2025
28 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $104 · 2021: $556 · 2022: $988 · 2023: $2,668 · 2024: $2,178 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,642 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,641.66 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,341.17 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Genzyme Corporation | $797.42 | 2019-2025 | |
| Lilly USA, LLC | $739.68 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $551.31 | 2020-2025 | Winlevi, Ilumya |
| Hill Dermaceuticals, INC. | $492.01 | 2023-2024 | Tolak |
| Pfizer INC. | $458.77 | 2023-2025 | |
| Janssen Biotech, INC. | $424.73 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $409.64 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| E.R. Squibb & Sons, L.L.C. | $402.24 | 2022-2025 | Sotyktu |
| Ucb, INC. | $356.14 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $266.12 | 2022-2023 | Vtama |
| Janssen Scientific Affairs, LLC | $210.06 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $188.79 | 2025 | Clindacin Etz, Neo-Synalar |
| Incyte Corporation | $171.09 | 2022-2024 | Opzelura |
| Amgen INC. | $169.26 | 2024-2025 | Otezla, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $141.30 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $134.67 | 2023-2025 | Cabtreo, Jublia |
| Celgene Corporation | $124.55 | 2019 | |
| Leo Pharma INC. | $112.33 | 2023-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $100.54 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.41 | 2024 | |
| Mayne Pharma Commercial LLC | $71.75 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $66.49 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $49.12 | 2025 | |
| Arcutis Biotherapeutics, INC. | $45.68 | 2024-2025 | Zoryve |
| Cipher Pharmaceuticals US LLC | $34.06 | 2025 | Spinosad, Natroba |
| Organon LLC | $20.50 | 2025 | Vtama |
| Botanix Sb INC | $17.55 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.